Archives 2019

Now Available: ARM’s Searchable, Downloadable Database of Near-Term Anticipated RM/AT Data Readouts and Other Clinical Events

This new resource provides clear, simplified information on indication-, technology-, or company-specific upcoming data readouts and other clinical events. ARM has carefully curated all entries to ensure they fall within our narrowly defined criteria for regenerative medicines, and includes many milestones which are not reported in other clinical trial datasets, including anticipated product approvals. Currently, the database includes 188 anticipated events and includes a search-and-download function, and

Read More


Researchers turn plastic water bottles into prosthetic limbs

Artificial limbs made out of plastic water bottles could save healthcare providers millions of pounds and help tackle pollution at the same time. An expert at De Montfort University Leicester (DMU) has successfully manufactured the first-of-its-kind prosthetic limb socket made from recycled plastic bottles. Dr K Kandan, senior lecturer in Mechanical Engineering at DMU, found he could

Read More


Stem cell-based bone and dental regeneration: a view of microenvironmental modulation

In modern medicine, bone and dental loss and defects are common and widespread morbidities, for which regenerative therapy has shown great promise. Mesenchymal stem cells, obtained from various sources and playing an essential role in organ development and postnatal repair, have exhibited enormous potential for regenerating bone and dental tissue. Currently, mesenchymal stem cells (MSCs)-based

Read More


Sarepta Duchenne drug rejected by FDA in surprise setback

In an unexpected decision, the Food and Drug Administration rejected Sarepta Therapeutics’ experimental drug for Duchenne muscular dystrophy, issuing on Monday a Complete Response Letter to the rare disease biotech.  According to Sarepta, the agency cited in its refusal infection risk tied to the drug’s delivery as well as preclinical signs of kidney toxicity. Called

Read More


FDA approves entrectinib which targets a key genetic driver of cancer, rather than a specific type of tumour

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to entrectinib, a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments. “We are in an exciting era of innovation in cancer treatment as we

Read More


Transplanted stem cells light up and enhance stroke recovery

When the mice brain cells glowed, the researchers knew they were onto something. The study, from a team at Emory University School of Medicine, Atlanta Veterans Affairs Medical Center and Tzu Chi University, announces a novel, non-invasive, regenerative method called optochemogenetics that could improve stroke recovery (J. Neuroscience10.1523/JNEUROSCI.2010-18.2019). The second leading cause of death worldwide, according to the World

Read More


Applied Bioengineering in Tissue Reconstruction, Replacement, and Regeneration

Source https://www.liebertpub.com/doi/pdf/10.1089/ten.teb.2018.0325 To this day, tissue reconstruction and replacement to address extensive tissue defects due to trauma, tumor resection, genetic and/or chronic diseases, or excessive debridement present a major clinical challenge. Traditional reconstructive techniques most commonly utilize autologous tissue. Undoubtedly, autologous composite tissue transfers or ‘‘flaps,’’ skin grafts, as well as the harvesting of bone

Read More